Royalty Pharma Declares Fourth-Quarter 2020 Dividend
October 15, 2020 09:15 ET
|
RP Management, LLC
NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2020 of $0.15 per class A...
Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders
October 13, 2020 16:10 ET
|
RP Management, LLC
NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today that certain selling shareholders intend to offer an aggregate 17,343,037 of the...
Royalty Pharma Announces Closing of $6.0 Billion Senior Unsecured Notes
September 02, 2020 16:25 ET
|
RP Management, LLC
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has closed an offering of $6 billion senior unsecured notes, comprised of the following...
Royalty Pharma Declares Third-Quarter 2020 Dividend
September 02, 2020 08:00 ET
|
RP Management, LLC
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2020 of $0.15 per class A...
Royalty Pharma Announces Pricing of $6.0 Billion Senior Unsecured Notes
August 25, 2020 08:00 ET
|
RP Management, LLC
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc announced today that it has priced an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively,...
Royalty Pharma Announces Launch of Senior Notes Offering
August 19, 2020 09:00 ET
|
RP Management, LLC
NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc announced today that it intends to offer, subject to market and other conditions, senior unsecured notes in multiple tranches (the...
Royalty Pharma Reports Second Quarter 2020 Results
August 12, 2020 07:00 ET
|
RP Management, LLC
Strong double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Receipts(1) (non-GAAP) Company introduces 2020 guidance: Adjusted Cash Receipts expected to be $1,720...
Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million
August 07, 2020 09:40 ET
|
RP Management, LLC
- Biohaven will receive up to $250 million to fund zavegepant’s development in migraine and non-migraine indications - Royalty Pharma to acquire up to a 3% royalty for zavegepant, a 0.4% royalty of...
Royalty Pharma Appoints Henry A. Fernandez and Ted W. Love, M.D. to the Company’s Board of Directors
August 03, 2020 16:15 ET
|
RP Management, LLC
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced the appointments of Henry A. Fernandez and Ted W. Love, M.D. to the company's Board of Directors, effective...
Royalty Pharma to Announce Second-Quarter 2020 Financial Results on August 12
July 20, 2020 16:15 ET
|
RP Management, LLC
NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (NASDAQ: RPRX) today announced that it will report its second quarter 2020 financial results on Wednesday, August 12, 2020, before the U.S....